San Diego, CA -- (SBWIRE) -- 09/15/2014 -- An investigation on behalf of investors of Hyperion Therapeutics Inc (NASDAQ:HPTX) shares over potential securities laws violations by Hyperion Therapeutics and certain of its directors and officers in connection certain financial statements was announced.

If you purchased shares of Hyperion Therapeutics Inc (NASDAQ:HPTX), you have certain options and you should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Hyperion Therapeutics Inc (NASDAQ:HPTX) concerning whether a series of statements by Hyperion Therapeutics regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Hyperion Therapeutics Inc reported that its annual Total Revenue rose to $42.20 million in 2013 and that its Net Loss of $32.26 million from 2012 turned to a Net Income of $16.63 million in 2013. Shares of Hyperion Therapeutics Inc (NASDAQ:HPTX) grew from $11.16 per share in January 2013 to as high as $31.00 per share in February 2014.

On September 8, 2014 Hyperion Therapeutics Inc (NASDAQ:HPTX) announced that it is terminating development of DiaPep277 for newly diagnosed Type 1 diabetes. Shares of Hyperion Therapeutics Inc (NASDAQ:HPTX) fell from $27.64 per share on September 5, 2014, to as low as $24.55 per share during September 8, 2014.

On September 11, 2014, NASDAQ:HPTX shares closed at $26.17

Those who purchased shares of Hyperion Therapeutics Inc (NASDAQ:HPTX) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com